Monoclonal antibodies have become an essential tool in biochemistry, molecular biology, and medicine, and basic and clinical investigators have been using them widely for research, diagnosis, and clinical therapy. The Monoclonal Antibodies Facility (MABF) was formally established in 2003. Its main goal is to produce high-affinity antibodies in a high-throughput and effective manner, while concentrating on quality of product and service. The MABF minimizes extensive hands-on procedures and standardizes protocols to provide accurate results and reproducibility.
Specific aims and long-term objectives are: 1) to produce high-affinity custom monoclonal antibodies for a wide range of research projects;2) to enable investigators to access highly-experienced personnel in hybridoma production and methodologies, and trouble-shoot any antigen or screening-related issues;3) to provide quality services at competitive prices;4) to gain insight, by means of the generated antibodies, into the role that different molecules play in normal and pathological systems, and characterize them for eventual therapy or diagnosis. The MABF occupies 726 sq. ft. in SCRB 1, home to the Center for Cancer Immunology Research (CCIR) on the South Campus which is equipped with customized laboratory services, centralized tissue culture rooms, liquid nitrogen tanks rooms, and glassware washing and sterilization facilities, all of which are available to the MABF. The MABF staff consists of Michel Gilliet, MD, Core Leader, is responsible for the direction of the core and chairs the oversight committee. Dr. Gilliet meets with Dr. Bover and Long Vien regularly concerning the overall operation of the MABF. Laura Bover, PhD, Core Co-Leader, is responsible for the overall operation of the MABF, for progress reports, interest researchers in the use of the facility and assures that procedural and policy changes are vetted with the oversight committee. She is responsible together with Long Vien of the short- and long-term planning and growth of the facility. Long Vien, Core Manager, is responsible for the day-to-day operations of the core. Together with Dr. Bover, he plans and designs technical procedures for the different user requirements. James Wygant, Coordinator Research Laboratory, is responsible for technical procedures and makes the first contact with users. He records all activities of the facility and follows-up with users, gathering information pertaining to publications, and grants used to cover the services. Rosa Munoz, Research Assistant, is responsible for technical procedures (hands-on). Future plans are to redesign our website to provide more information on services and benefits in an effort to reach more researchers inside MDACC. The facility also needs to communicate more broadly about the unique value-added features of its services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-37S2
Application #
8530392
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
37
Fiscal Year
2012
Total Cost
$2,882
Indirect Cost
$1,058
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Ji, Shuang; Ning, Jing; Qin, Jing et al. (2018) Conditional independence test by generalized Kendall's tau with generalized odds ratio. Stat Methods Med Res 27:3224-3235
McNeill, Lorna H; Reitzel, Lorraine R; Escoto, Kamisha H et al. (2018) Engaging Black Churches to Address Cancer Health Disparities: Project CHURCH. Front Public Health 6:191
Hosry, Jeff; Miranda, Roberto N; Samaniego, Felipe et al. (2018) Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients. Int J Cancer 142:940-948
Parkes, Amanda; Clifton, Katherine; Al-Awadhi, Aydah et al. (2018) Characterization of bone only metastasis patients with respect to tumor subtypes. NPJ Breast Cancer 4:2
Raber, Margaret; Huynh, To Nhu; Crawford, Karla et al. (2018) Development and Feasibility of a Community-Based, Culturally Flexible Colorectal Cancer Prevention Program. J Community Health 43:882-885
Wang, Xiaoxiao; Cao, Xin; Sun, Ruifang et al. (2018) Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Neoplasia 20:574-593
Koay, Eugene J; Owen, Dawn; Das, Prajnan (2018) Radiation-Induced Liver Disease and Modern Radiotherapy. Semin Radiat Oncol 28:321-331
Zhang, Yan; Coletta, Adriana M; Allen, Pamela K et al. (2018) Perirenal Adiposity is Associated With Lower Progression-Free Survival From Ovarian Cancer. Int J Gynecol Cancer 28:285-292
Rausch, Caitlin R; DiPippo, Adam J; Bose, Prithviraj et al. (2018) Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole. Clin Infect Dis 67:1610-1613
Gu, Shenda; Ngamcherdtrakul, Worapol; Reda, Moataz et al. (2018) Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment. PLoS One 13:e0198141

Showing the most recent 10 out of 12418 publications